◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › U › URGN

UroGen Pharma Ltd (URGN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-06

UroGen Pharma Ltd (URGN) operates in the BIOTECHNOLOGY industry and is headquartered in Princeton, United States with about 300 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, URGN reported $110M in revenue and ($153M) in net income.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.

Interactive charts & full statements → Open the URGN valuation workbench →

URGN Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Revenue	$188M	$110M	$90M	$83M	$64M	$48M	$12M	$0M	$1M	$8M	$18M	$0M	$0M	$0M
Gross Profit	$172M	$97M	$82M	$73M	$57M	$43M	$11M	$0M	($1M)	$8M	$18M	$0M	$0M	$0M
Gross Margin %	91.5%	88.7%	90.2%	88.7%	88.1%	89.3%	91.5%	100.0%	-59.8%	92.7%	99.8%	—	—	—
Operating Income (EBIT)	($66M)	($125M)	($97M)	($66M)	($79M)	($92M)	($127M)	($109M)	($77M)	($20M)	$1M	($12M)	($4M)	($3M)
Operating Margin %	-35.1%	-113.7%	-107.1%	-79.2%	-122.8%	-192.1%	-1074.2%	-608211.1%	-6842.2%	-244.6%	4.5%	—	—	—
Net Income	($97M)	($153M)	($127M)	($102M)	($110M)	($111M)	($128M)	($105M)	($76M)	($20M)	($2M)	($13M)	($5M)	($3M)
Net Margin %	-51.6%	-139.8%	-140.3%	-123.6%	-170.6%	-230.7%	-1088.9%	-584144.4%	-6707.2%	-245.2%	-11.1%	—	—	—
EBITDA	($71M)	($136M)	($95M)	($60M)	($76M)	($109M)	($125M)	($108M)	($77M)	($20M)	$1M	($12M)	($4M)	($3M)
Earnings Per Share (EPS)	$-1.98	$-3.19	$-2.96	$-3.55	$-4.81	$-4.96	$-5.90	$-5.12	$-4.80	$-2.06	$-0.16	$-5.51	$-1.98	$-1.56
Shares Outstanding (M)	50M	48M	43M	29M	23M	22M	22M	21M	16M	10M	—	2M	2M	2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

URGN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$72M	$51M	$38M	$27M	$24M	$20M	$25M	$25M
Gross Profit	$66M	$47M	$35M	$24M	$21M	$18M	$22M	$23M
Gross Margin %	90.9%	91.9%	91.3%	88.1%	85.3%	88.5%	89.9%	90.3%
Operating Income (EBIT)	$0M	($20M)	($19M)	($27M)	($41M)	($37M)	($28M)	($18M)
Operating Margin %	0.1%	-39.8%	-50.5%	-99.7%	-171.2%	-182.3%	-112.6%	-69.6%
Net Income	($14M)	($24M)	($26M)	($33M)	($50M)	($44M)	($38M)	($24M)
Net Margin %	-19.8%	-46.3%	-69.7%	-121.3%	-206.2%	-216.5%	-152.7%	-93.9%
EBITDA	($4M)	($19M)	($22M)	($26M)	($49M)	($39M)	($26M)	($15M)
Earnings Per Share (EPS)	$-0.28	$-0.47	$-0.54	$-0.69	$-1.05	$-0.92	$-0.80	$-0.55
Shares Outstanding (M)	50M	50M	49M	48M	48M	47M	47M	43M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

URGN Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Cash from Operations (CFO)	($158M)	($162M)	($97M)	($76M)	($88M)	($85M)	($106M)	($71M)	($37M)	($10M)	$4M	($7M)	($4M)	($3M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$1M	$1M	$0M	$1M	$0M	$1M	$0M	$0M	$0M
Free Cash Flow (FCF)	($158M)	($163M)	($97M)	($77M)	($88M)	($86M)	($107M)	($71M)	($38M)	($10M)	$3M	($7M)	($4M)	($3M)
FCF Margin %	-84.0%	-148.2%	-107.4%	-92.6%	-136.5%	-178.3%	-907.7%	-396344.4%	-3359.4%	-120.6%	19.9%	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

URGN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($33M)	($45M)	($38M)	($42M)	($40M)	($42M)	($14M)	($28M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($33M)	($45M)	($38M)	($42M)	($40M)	($42M)	($14M)	($28M)
FCF Margin %	-45.6%	-89.0%	-101.3%	-154.1%	-165.1%	-207.7%	-55.9%	-110.1%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

URGN Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Assets	$253M	$200M	$286M	$178M	$136M	$120M	$122M	$202M	$104M	$76M	$23M	$19M	$4M	$3M
Cash & Cash Equivalents	$79M	$111M	$172M	$95M	$55M	$44M	$53M	$50M	$101M	$37M	$21M	$18M	$4M	$3M
Total Liabilities	$385M	$306M	$295M	$244M	$225M	$111M	$26M	$22M	$13M	$7M	$7M	$2M	$1M	$0M
Total Debt (Short + Long-Term)	$191M	$122M	$123M	$99M	$98M	$3M	$2M	$0M	$0M	$0M	$4M	$1M	$0M	$0M
Total Shareholders' Equity	($132M)	($105M)	($9M)	($65M)	($89M)	$8M	$96M	$180M	$90M	$69M	$16M	$17M	$3M	$3M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive URGN viewer.

Other Companies in BIOTECHNOLOGY

OCUL · Ocular Therapeutix Inc — $2 billion
PVLA · Palvella Therapeutics, Inc — $2 billion
TRVI · Trevi Therapeutics Inc — $2 billion
SRPT · Sarepta Therapeutics Inc — $2 billion
BHVN · Biohaven Ltd. — $2 billion
KOD · Kodiak Sciences Inc — $2 billion
NUVB · Nuvation Bio Inc — $2 billion
RXRX · Recursion Pharmaceuticals Inc — $2 billion

← URE All “U” companies URI →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.